Mifepristone

Ongoing support for forgoing Rh testing in early pregnancy, medication abortion before six weeks, provider bias on contraceptive counseling adolescents, and local anesthesia before procedural abortion.

U.S. MEC and U.S. SPR, standard dosing of UPA EC for people of all body sizes, birth control information on TikTok, and safety of medication abortion without screening ultrasound.

Doctor-messengers are valuable communicators about abortion, impact of the shot on medication abortion efficacy, common misconceptions about IUDs, and precoital EC.

Factors that increase risk for deep or nonpalpable implant, 12-hour vs. 24-hour mifepristone-misoprostol interval, and two studies reinforcing the safety and efficacy of no-test medication abortion.

Young people’s concerns about birth control and fertility, expanding EPT and PrEP in the ED, spike in EC demand around the New Year, and abortion decision making.

Pain management in abortion care, risk of Rh sensitization with abortion before 12 weeks’ gestation, and contraception information on TikTok.

Answers for pharmacists (and other providers) about the current status of mifepristone.

Men’s willingness to use novel birth control, characteristics of patients seeking telehealth medication abortion care, mifepristone as a potential treatment for adenomyosis, and the impact of the pill on adolescent bone health.